Abstract | BACKGROUND AND AIMS: PATIENTS AND METHODS: RESULTS: A total of 49 cycles (median 2, range 1-6) was administered to 20 patients. The median follow-up was 8 months (range 3-24). Of the 20 patients, 1 had a complete response, 6 had a partial response, 6 had stable and 7 had progressive disease. Median time to progression for all patients was 4 months (95% Cl 1.7-5.6). The median overall survival for all patients was 8 months (95% CI 5.7-10.3). The major toxicity was myelosuppression. Neutropenia of grade 3 or more occurred in 13 patients (65%), and thrombocytopenia of grade 3 occurred in 1 patient (5%). Febrile neutropenia was observed in 1 patient (5%). There was no treatment-related mortality. CONCLUSION:
|
Authors | Toshiaki Tanaka, Hiromasa Fujita, Susumu Sueyoshi, Yuichi Tanaka, Hiroko Sasahara, Naoki Mori, Tsuyoshi Nagano, Hideaki Yamana, Kazuo Shirouzu |
Journal | Chemotherapy
(Chemotherapy)
Vol. 53
Issue 6
Pg. 449-53
( 2007)
ISSN: 1421-9794 [Electronic] Switzerland |
PMID | 17952006
(Publication Type: Journal Article)
|
Copyright | (c) 2007 S. Karger AG, Basel. |
Chemical References |
- Taxoids
- Docetaxel
- Cisplatin
- Fluorouracil
|
Topics |
- Adrenal Gland Neoplasms
(drug therapy, secondary)
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bone Neoplasms
(drug therapy, secondary)
- Cisplatin
(administration & dosage)
- Docetaxel
- Esophageal Neoplasms
(drug therapy, pathology, surgery)
- Feasibility Studies
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Lung Neoplasms
(drug therapy, secondary)
- Lymphatic Metastasis
(pathology)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, pathology)
- Salvage Therapy
- Survival Rate
- Taxoids
(administration & dosage)
- Treatment Outcome
|